Catechin

Catechin

SCHEMBL10001669

Oc1cc(O)c2c(c1)OC(c1ccc(O)c(O)c1)C(O)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 6/20 1.00
KDM4E B2RXH2 6/20 1.00
HSD17B10 Q99714 5/20 1.00
SNCA P37840 5/20 1.00
ALDH1A1 P00352 4/20 1.00
MAPT P10636 4/20 1.00
PTGS1 P23219 4/20 1.00
ALOX15 P16050 4/20 1.00
GAA P10253 3/20 1.00
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
APEX1 P27695 3/20 1.00
RECQL P46063 3/20 1.00
CYP3A4 P08684 3/20 1.00
PKM P14618 2/20 1.00
ALPL P05186 2/20 1.00
POLB P06746 2/20 1.00
PTGS2 P35354 2/20 1.00
RAD52 P43351 2/20 1.00
HPGD P15428 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(+)-Epicatechin SCHEMBL862089 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
Cianidanol SCHEMBL1330653 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
Catechin SCHEMBL10033927 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
(-)-Epicatechin SCHEMBL19412 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
Cianidanol SCHEMBL12392372 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
Cianidanol SCHEMBL13610161 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
Catechin SCHEMBL19411 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
Cianidanol SCHEMBL19741 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
Cianidanol SCHEMBL5081456 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
(-)-Catechin SCHEMBL166733 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118103078-A Stabilized compositions of radionuclides and uses thereof 瑞择生物公司 2024-05-28 CN claimed
EP-0137832-B1 PHARMACEUTICAL COMPOSITIONS OF ANTI-PANCREATIC INFLAMMATORY EFFECT BIOGAL GYOGYSZERGYAR (HU) 1987-08-12 EP claimed
JP-56016412-A None JP disclosed
EP-4543959-B1 SOLUTION OF POLYPHENOLS IN AMINE SIKA TECH AG (CH) 2026-05-13 EP disclosed
EP-4543959-A1 SOLUTION OF POLYPHENOLS IN AMINE Sika Technology AG (CH) 2025-04-30 EP disclosed
CN-118103078-A Stabilized compositions of radionuclides and uses thereof 瑞择生物公司 2024-05-28 CN disclosed
WO-2023247445-A1 SOLUTION OF POLYPHENOLS IN AMINE SIKA TECHNOLOGY AG (CH) 2023-12-28 WO disclosed
EP-4296291-A1 SOLUTION OF POLYPHENOLS IN AMINE Sika Technology AG (CH) 2023-12-27 EP disclosed
US-20230310461-A1 Compositions and Methods for Treatment of Prediabetes CROSS III WILLIAM H (US) 2023-10-05 US disclosed
US-20230310461-A1 Compositions and Methods for Treatment of Prediabetes CROSS III WILLIAM H (US) 2023-10-05 US disclosed
WO-2023117847-A1 USE OF CATECHIN FOR THE TREATMENT OF FGFR-RELATED BONE REPAIR AND BONE FORMATION IMPAIRMENT INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2023-06-29 WO disclosed
EP-0065123-B1 HARDLY SOLUBLE SALTS OF AMINOGLYCOSIDE ANTIBIOTICS MERCK PATENT GmbH (DE) 1984-07-25 EP disclosed
US-4461907-A Amino-substituted flavans useful as anti-viral agents BURROUGHS WELLCOME CO. 1984-07-24 US disclosed
EP-0065123-A1 Hardly soluble salts of aminoglycoside antibiotics MERCK PATENT GmbH (DE) 1982-11-24 EP disclosed
EP-0004579-B1 FLAVANS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM THE WELLCOME FOUNDATION LIMITED (GB) 1982-08-18 EP disclosed
EP-0051061-A2 Novel intermediates and process for their preparation THE WELLCOME FOUNDATION LIMITED (GB) 1982-05-05 EP disclosed
US-4285964-A AMINE SALTS OF LYSINE OR ARGININE; BONE DISORDERS; JOINTS; CONNECTIVE TISSUE; ANTIINFLAMMATORY AGENTS; SOLUBILITY CONTINENTAL PHARMA (BE) 1981-08-25 US disclosed
US-4268517-A (+)-CATECHIN CONTINENTAL PHARMA (BE) 1981-05-19 US disclosed
JP-S5616412-A CARCINOSTATIC AGENT KANEBO LTD 1981-02-17 JP disclosed
EP-0004579-A1 Flavans, process for their preparation and pharmaceutical compositions containing them THE WELLCOME FOUNDATION LIMITED (GB) 1979-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310461-A1 Compositions and Methods for Treatment of Prediabetes GPX1, GPX4, NFE2L2 BACE1 1069/4885KDM4E 4445/4885HSD17B10 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.